Identification of the active GSK3β increase in PBMCs in DM1 patients allows for the detection of pathological GSK3β elevation in blood samples, eliminating the need for muscle biopsies in clinical studies. The gene discussed is GSK3B; the disease is myotonic dystrophy type 1.